A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
A Phase 1a/b, Multicenter, Open-label, First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
Sponsor: Fortvita Biologics (USA)Inc.
A PHASE1 clinical study on Locally Advanced Unresectable or Metastatic Solid Tumors, this trial is actively recruiting participants. The trial is conducted by Fortvita Biologics (USA)Inc. and has accumulated 7 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
7 versions recorded-
Dec 2025 — Present [monthly]
Recruiting PHASE1
-
May 2025 — Dec 2025 [monthly]
Recruiting PHASE1
-
Nov 2024 — May 2025 [monthly]
Recruiting PHASE1
-
Sep 2024 — Nov 2024 [monthly]
Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
▶ Show 2 earlier versions
-
Dec 2022 — Jul 2024 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Sep 2022 — Dec 2022 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Fortvita Biologics (USA)Inc.
- Innovent Biologics (Suzhou) Co. Ltd.
- TigerMed
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Austin, United States , Beijing, China , Benowa, Australia , Birtinya, Australia , Changsha, China , Chengdu, China , Darlinghurst, Australia , Fuzhou, China , Guangzhou, China , Hangzhou, China and 18 more locations